חוב כולל להון: Monopar Therapeutics Inc. (MNPR)

The price history on the Monopar Therapeutics (MNPR) chart reflects the dynamics of the total debt-to-equity ratio, which currently stands at 0.00. The business relies on the neutral political status of medicine, which shields the company from sanctions and external shocks. The strategy is based on developing radiopharmaceuticals for various tumor types to minimize the probability of failure. The team consists of leading oncologists who value scientific independence and state-of-the-art laboratory equipment.

For the biotechnology sector where Monopar Therapeutics conducts its research and development, financial leverage determines business resilience. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed funds within the asset structure. An increase in this coefficient signals elevated bankruptcy risks. This is critical for Monopar Therapeutics (MNPR), as the debt load could shorten the runway amid a high cash burn. Monitoring this metric allows investors to avoid purchasing an asset overburdened with liabilities.